Stem Cell Innovations and Twente University to Evaluate Bone Forming Capacity of PluriCells(TM).

HOUSTON & ENSCHEDE, Netherlands -- Stem Cell Innovations, Inc. (OTCBB:SCLL) announced today that the Company has initiated a collaboration with the University of Twente (the Netherlands) to explore the bone forming properties of PluriCells. Under the material transfer agreement, the University of Twente will get access to Stem Cell Innovations (SCI) proprietary human pluripotent stem cell technology and know-how. In return SCI will receive a nonexclusive license to intellectual property generated with the PluriCells.

"The team of professor van Blitterswijk is one of the world's leading academic groups in the study of stem cell derived bone and cartilage formation. This former IsoTis in-house orthobiology research group has developed a comprehensive set of robust in vitro and in vivo models in which the PluriCells will be tested", said Stem Cell Innovations CEO Dr. James Kelly. "SCI is impressed that their science is very application driven, with van Blitterswijk as founder of several biotech companies, including IsoTis, where he was CEO".

"We are very pleased to work with the PluriCells provided by Stem Cell Innovations", said Prof. Dr. Clemens van Blitterswijk. "SCI has developed a unique cell culture system that makes culturing of human pluripotent stem cells much more straightforward. I expect that our stem cell research team, headed by Dr. Jan de Boer, will extrapolate recent results with murine stem cells to human bone tissue engineering using PluriCells".

Stem Cell Innovations recently disclosed it has produced multiple lines of human pluripotent stem cells. These PluriCell[TM] lines can be efficiently cultured in tissue culture plates without the use of feeder layers and can be efficiently differentiated into multiple cell-types, having the potential to aid in drug discovery and development.

PluriCells[TM] are a type of pluripotent stem cell isolated from fetal tissue that have the ability to become all cell types of the body. Because they are developed from fetal germ cells, not viable embryos, they are eligible to be used in any NIH funded laboratory. Stem cells derived from fetal germ cells were explicitly excluded from the Presidential ban by the Department of Health and Human Services guidance document of March 19, 2002, that laid out what type of stem cells could and could not be used in Federally funded research (for the actual document see: http://www.hhs.gov/ohrp/humansubjects/guidance/stemcell.pdf).

About Stem Cell Innovations, Inc.

SCI is a cell biology company with offices in Scotch Plains, N.J., Houston, TX and in Leiden, the Netherlands. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells[TM], have the potential to aid in drug discovery, toxicology, and cell therapy. Stem Cell Innovations is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.

Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands the Company's currently marketed C3A human liver cell-based toxicology offerings.

Additional information is available at www.stemcellinnovations.com.

PluriCells is a Trademark of Stem Cell Innovations, Inc.

About University of Twente

The University of Twente is an entrepreneurial research university. It was founded in 1961 and offers education and research in areas ranging from public policy studies and applied physics to biomedical technology.

BMTI is the institute of the University of Twente where all research activities in the (bio) medical field are brought together. BMTI projects contribute to improving the quality of life of human beings, by restoring bodyperformance whenever there is a need to, because of loss of function through diseases, accidents or more age-related deterioration of human functioning.

In the multidisciplinary research of BMTI eleven different groups of the University participate by combining their technical expertise with the know-how and day-to-day experiences of (bio-) medical practice. Depending on the problem, BMTI's research may focus on various issues from (early) diagnostics through medical intervention, cure, care and more rehabilitation related activities.

Through a long history of biomedical research in the University of Twente, BMTI is recognised world-wide as a leading institute in this multidisciplinary field of science where engineering concepts and methods are employed to solve and understand medical and biological problems.

Forward-Looking Statement

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Forward-Looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because theses forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more or these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.